Analysts' ratings for Axonics AXNX over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 5 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $71.29, a high estimate of $73.00, and a low estimate of $71.00. Witnessing a positive shift, the current average has risen by 0.69% from the previous average price target of $70.80.
Analyzing Analyst Ratings: A Detailed Breakdown
The perception of Axonics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Shagun Singh | RBC Capital | Maintains | Sector Perform | $71.00 | - |
| David Rescott | Truist Securities | Lowers | Hold | $71.00 | $73.00 |
| David Rescott | Truist Securities | Lowers | Hold | $71.00 | $73.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $71.00 | $75.00 |
| Mike Kratky | Leerink Partners | Announces | Market Perform | $71.00 | - |
| Larry Biegelsen | Wells Fargo | Raises | Equal-Weight | $71.00 | $68.00 |
| David Rescott | Truist Securities | Raises | Buy | $73.00 | $65.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axonics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axonics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Axonics's stock. This examination reveals shifts in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Axonics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Axonics analyst ratings.
All You Need to Know About Axonics
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention.
Financial Milestones: Axonics's Journey
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Axonics displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 32.27%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.22%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.65%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Axonics's ROA stands out, surpassing industry averages. With an impressive ROA of 0.6%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Axonics adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Basics of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
